{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:36:24Z","timestamp":1761744984204},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are &amp;gt;60 years of age. Patients with relapsed\/refractory (rr) disease have a poor prognosis with currently available treatments. Lenalidomide is available in Italy for patients with rrDLBCL based on a local disposition of the Italian Drug Agency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Subjects, Materials, and Methods<\/jats:title>\n                  <jats:p>An observational retrospective study was conducted in 24 Italian hematology centers with the aim to improve information on effectiveness and safety of lenalidomide use for rrDLBCL in real practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred fifty-three patients received lenalidomide for 21\/28 days with a median of four cycles. At the end of therapy, there were 36 complete responses (23.5%) and 9 partial responses with an overall response rate (ORR) of 29.4%. In the elderly (&amp;gt;65 years) subset, the ORR was 33.6%. With a median follow-up of 36 months, median overall survival was reached at 12 months and median disease-free survival was not reached at 62 months. At the latest available follow-up, 29 patients are still in response out of therapy. Median progression-free survivals differ significantly according to age (2.5 months vs. 9.5 in the younger vs. elderly group, respectively) and to disease status at the latest previous therapy (15 months for relapsed patients vs. 3.5 for refractory subjects). Toxicities were manageable, even if 30 of them led to an early drug discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lenalidomide therapy for patients with rrDLBCL is effective and tolerable even in a real-life context, especially for elderly patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and approximately 50% of the patients are &amp;gt;60 years of age. Patients with relapsed\/refractory (rr) disease have a poor prognosis, reflected by the remarkably short life expectancy of 12 months with currently available treatments. The rrDLBCL therapeutic algorithm is not so well established because data in the everyday clinical practice are still poor. Lenalidomide for patients with rrDLBCL is effective and tolerable even in a real-life context, especially for elderly patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0603","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T18:05:34Z","timestamp":1554228334000},"page":"1246-1252","source":"Crossref","is-referenced-by-count":14,"title":["Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice"],"prefix":"10.1093","volume":"24","author":[{"given":"Alessandro","family":"Broccoli","sequence":"first","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[{"name":"Hematology, Citt\u00e0 della Salute e della Scienza Hospital and University, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"Hematology Unit, S. Maria delle Croci Hospital, Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cascavilla","sequence":"additional","affiliation":[{"name":"Hematology Department, \u201cCasa Sollievo della Sofferenza\u201d Hospital, IRCCS \u2013 Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Conconi","sequence":"additional","affiliation":[{"name":"Hematology Division, Ospedale degli Infermi di Biella, Ponderano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Balzarotti","sequence":"additional","affiliation":[{"name":"Departmento of Medical Oncology and Hematology Humanitas Cancer Center, Rozzano-Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Christina","family":"Cox","sequence":"additional","affiliation":[{"name":"Hematology unit, Azienda ospedaliera universitaria Sant'Andrea, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Marino","sequence":"additional","affiliation":[{"name":"Dipartimento di Oncologia Clinica e Sperimentale, Oncologia Medica 1, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cecilia","family":"Goldaniga","sequence":"additional","affiliation":[{"name":"Hematology Department IRCCS \u201cOspedale Maggiore Policlinico\u201d Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Tecchio","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Verona University, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"Department of Hematology Azienda Ospedali Riuniti Villa Sofia- Cervello, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Devizzi","sequence":"additional","affiliation":[{"name":"Division of Hematology, IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Monaco","sequence":"additional","affiliation":[{"name":"Hematology Unit, SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU Policlinico-OVE, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Fama","sequence":"additional","affiliation":[{"name":"Hematology AUSL-IRCCS, Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Zancanella","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Niguarda Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Paolini","sequence":"additional","affiliation":[{"name":"Rovigo's Hematology Department, Rovigo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[{"name":"Hematology, AOU Careggi, Firenze, Italy"},{"name":"Hematology Azienda San Camillo Forlanini, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Castellino","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera S. Croce e Carle - Hematology Department and BMT Unit, Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Unit of Hematology with Transplantation Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"2021122507523601900_onco12931-bib-0001","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122507523601900_onco12931-bib-0002","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122507523601900_onco12931-bib-0003","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"2021122507523601900_onco12931-bib-0004","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/107327481201900305","article-title":"Diffuse large B-cell lymphoma: Current strategies and future directions","volume":"19","author":"Cultrera","year":"2012","journal-title":"Cancer Control"},{"key":"2021122507523601900_onco12931-bib-0005","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507523601900_onco12931-bib-0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/2278-330X.126531","article-title":"Management of relapsed-refractory diffuse large B cell lymphoma","volume":"3","author":"Raut","year":"2014","journal-title":"South Asian J Cancer"},{"key":"2021122507523601900_onco12931-bib-0007","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122507523601900_onco12931-bib-0008","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2021122507523601900_onco12931-bib-0009","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122507523601900_onco12931-bib-0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","article-title":"Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma","volume":"93","author":"Vacirca","year":"2014","journal-title":"Ann Hematol"},{"key":"2021122507523601900_onco12931-bib-0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A multicenter study of KTE-C19 Anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"2021122507523601900_onco12931-bib-0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1634\/theoncologist.2013-0020","article-title":"The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: Summary of the scientific assessment of the committee for medicinal products for human use","volume":"18","author":"Pean","year":"2013","journal-title":"The Oncologist"},{"key":"2021122507523601900_onco12931-bib-0013","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 (CRBN.)","volume":"164","author":"Ghandi","year":"2014","journal-title":"Br. J Haematol"},{"key":"2021122507523601900_onco12931-bib-0014","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated Cd20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122507523601900_onco12931-bib-0015","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"2021122507523601900_onco12931-bib-0016","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122507523601900_onco12931-bib-0017","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non- Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122507523601900_onco12931-bib-0018","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122507523601900_onco12931-bib-0019","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122507523601900_onco12931-bib-0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/187152011795347487","article-title":"Lenalidomide - Current understanding of mechanistic properties","volume":"11","author":"Tageja","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"2021122507523601900_onco12931-bib-0021","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3109\/10428194.2014.964702","article-title":"Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: An Italian observational multicenter retrospective study in daily clinical practice","volume":"56","author":"Zinzani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2021122507523601900_onco12931-bib-0022","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1634\/theoncologist.2016-0103","article-title":"Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: Is it a valid treatment option?","volume":"21","author":"Mondello","year":"2016","journal-title":"The Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0603","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1246\/41918377\/oncolo_24_9_1246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1246\/41918377\/oncolo_24_9_1246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:53:58Z","timestamp":1640418838000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/9\/1246\/6439319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,4,2]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0603","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,4,2]]}}}